The active ingredient in Genfulin^® is molgramostim (recombinant human granulocyte/ macrophage colony-stimulating factor,
rhGM-CSF [rDNA origin]) produced by GenScis patented E.coli secretion technology. Clinical trials show its efficacy in actively accelerating wound healing, increasing wound tearing-resistance, and reducing, even avoiding, scar proliferation in burn
patients. Genfulin^® is used in the treatment of deep II-degree burns and wound healing.

Strengths:
          *   100 μg rhGM-CSF/10g/tube

Features:
          *   The worlds only topical rhGM-CSF gel made by patented E.coli secretion technology
          *   The 1^st novel and unique formulation to treat burns

Indications:
          *   Deep II-degree burns
          *   Wound healing

How to use:
          *   Apply the gel to the wound after cleaning with sterile saline water. Apply the gel to the inner layer of the wound
dressing directly when needed.
          *   Dose is base on the size of the wound. 100cm² wound/tube is recommended, once per day. The period of treatment
is from 7 days to 28 days.
          *   Currently, there is no clinical experience for the wound area more than 100 cm².